Literature DB >> 28152124

Structural and Functional Recovery Following Limited Iatrogenic Macular Detachment for Retinal Gene Therapy.

Matthew P Simunovic1, Kanmin Xue2, Jasleen K Jolly2, Robert E MacLaren3.   

Abstract

IMPORTANCE: The early decline and recovery of retinal structure and function following iatrogenic macular detachment for retinal gene therapy is not well characterized in those with relatively preserved central visual function. Here, the recovery of retinal structure and function over the first month following iatrogenic retinal detachment for the delivery of adeno-associated viral vector encoding Rab Escort Protein 1 is described as a part of gene therapy for choroideremia.
OBJECTIVE: To study changes in both retinal structure and function during the first month following iatrogenic macular detachment surgery. DESIGN, SETTING, AND PARTICIPANTS: This prospective interocularly controlled study was conducted between February 1 and December 31, 2015. Treatment consisted of a subretinal injection of 0.1 mL of a gene therapy solution containing 1 × 1011 viral particles performed unilaterally. The participants were 5 males, aged 23 to 71 years, with a clinical and genetic diagnosis of choroideremia. MAIN OUTCOMES AND MEASURES: Retinal structure and function were assessed at baseline, 1 week, and 1 month using optical coherence tomography, logMAR visual acuity, microperimetry, the Farnsworth-Munsell (FM) 100-hue test, and the Rayleigh match.
RESULTS: Five white male patients aged 23 to 71 years underwent unilateral subretinal gene therapy for genetically confirmed choroidermeia. Optical coherence tomographic images demonstrated a complete resolution of the resulting iatrogenic retinal detachment by 1 week in all 5 patients. At 1 month, the mean (SE) change in central foveal thickness was +9.6 (7.2) μm in treated eyes and +8.8 (12.6) μm in control eyes. The mean (SE) change in visual acuity was +5.4 (3.3) letters in treated eyes and +0.8 (3.1) letters in control eyes. At 1 month, the mean (SE) threshold sensitivity changes were -1.2 (2.1) dB in treated eyes and -1.0 (1.2) dB in control eyes. Color discrimination at the FM 100-hue changed little at 1 month (mean [SE] change in C-index, -0.2 [0.4] in treated eyes and 0.1 [0.2] in control eyes). Rayleigh matches in 1 patient were consistent with a diagnosis of pseudoprotanomaly, suggesting decreased effective optical density of the cone photopigments. CONCLUSIONS AND RELEVANCE: Retinal structural recovery-as assessed by optical coherence tomography-occurs soon after iatrogenic detachment. Similarly, visual acuity recovers or improves within 1 month of the procedure and may not be accompanied by improvements in threshold sensitivity or color discrimination. Changes in color matching in 1 patient suggest decreased optical density of the cone photopigments in the early postoperative period.

Entities:  

Mesh:

Year:  2017        PMID: 28152124     DOI: 10.1001/jamaophthalmol.2016.5630

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  14 in total

Review 1.  Gene therapy and genome surgery in the retina.

Authors:  James E DiCarlo; Vinit B Mahajan; Stephen H Tsang
Journal:  J Clin Invest       Date:  2018-06-01       Impact factor: 14.808

2.  Colour discrimination ellipses in choroideremia.

Authors:  Immanuel P Seitz; Jasleen K Jolly; M Dominik Fischer; Matthew P Simunovic
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-05       Impact factor: 3.117

3.  Retinal gene therapy: an eye-opener of the 21st century.

Authors:  Anne Louise Askou; Thomas Stax Jakobsen; Thomas J Corydon
Journal:  Gene Ther       Date:  2020-06-19       Impact factor: 5.250

4.  Multimodal imaging reveals retinoschisis masquerading as retinal detachment in patients with choroideremia.

Authors:  Luciano C Greig; Karen G Gutierrez; Jin Kyun Oh; Sarah R Levi; Edward Korot; Stephen H Tsang; Vinit B Mahajan
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-20

5.  Impact of Vital Dyes on Cell Viability and Transduction Efficiency of AAV Vectors Used in Retinal Gene Therapy Surgery: An In Vitro and In Vivo Analysis.

Authors:  Anna P Salvetti; Maria I Patrício; Alun R Barnard; Harry O Orlans; Doron G Hickey; Robert E MacLaren
Journal:  Transl Vis Sci Technol       Date:  2017-07-10       Impact factor: 3.283

6.  Fasudil, a Clinically Used ROCK Inhibitor, Stabilizes Rod Photoreceptor Synapses after Retinal Detachment.

Authors:  Ellen Townes-Anderson; Jianfeng Wang; Éva Halász; Ilene Sugino; Amy Pitler; Ian Whitehead; Marco Zarbin
Journal:  Transl Vis Sci Technol       Date:  2017-06-20       Impact factor: 3.283

7.  Characterizing the Natural History of Visual Function in Choroideremia Using Microperimetry and Multimodal Retinal Imaging.

Authors:  Jasleen K Jolly; Kanmin Xue; Thomas L Edwards; Markus Groppe; Robert E MacLaren
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-10-01       Impact factor: 4.799

8.  Perspectives on Gene Therapy: Choroideremia Represents a Challenging Model for the Treatment of Other Inherited Retinal Degenerations.

Authors:  Ian M MacDonald; Christopher Moen; Jacque L Duncan; Stephen H Tsang; Jasmina Cehajic-Kapetanovic; Tomas S Aleman
Journal:  Transl Vis Sci Technol       Date:  2020-02-14       Impact factor: 3.283

9.  ROCK inhibition reduces morphological and functional damage to rod synapses after retinal injury.

Authors:  Éva Halász; Marco A Zarbin; Amy L Davidow; Laura J Frishman; Peter Gombkoto; Ellen Townes-Anderson
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

10.  Ocular gene therapy for choroideremia: clinical trials and future perspectives.

Authors:  Kanmin Xue; Robert E MacLaren
Journal:  Expert Rev Ophthalmol       Date:  2018-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.